Literature DB >> 22265943

Dementia is associated with insulin resistance in patients with Parkinson's disease.

Domenico Bosco1, Massimiliano Plastino, Dario Cristiano, Carmela Colica, Caterina Ermio, Matteo De Bartolo, Pasquale Mungari, Giulia Fonte, Domenico Consoli, Arturo Consoli, Antonietta Fava.   

Abstract

BACKGROUND: Parkinson's disease is a neurodegenerative disorder involving the basal ganglia. Type-2 Diabetes Mellitus is an important risk factor for Alzheimer disease and vascular dementia. However, the association between Parkinson's disease and Diabetes Mellitus is controversial.
OBJECTIVE: To investigate glucose metabolism abnormalities in 110 Parkinson's disease patients with and without dementia. SUBJECTS AND METHODS: We evaluated Insulin Resistance, glucose and insulin levels after a 2-h-oral-glucose-tolerance-test in 53 Parkinson's disease with dementia and 57 with Parkinson's disease without dementia, with normal fasting glucose.
RESULTS: BMI, waist circumference, fasting glucose and insulin values, HbA1c, triglycerides, blood lipid profile, depression rating, educational levels, levodopa-dosage and antipsychotic use were similar in both groups. Disease duration and motor impairment were higher in patients with Parkinson's disease and dementia group. After 2-h-oral-glucose-tolerance-test, the prevalence of glucose metabolism abnormalities was significantly higher in group with Parkinson's disease and dementia group (p=0.03). The insulin resistance was present in 62% patients with Parkinson's disease with dementia, of whom 30% had also impaired glucose tolerance, 5,6% newly diagnosed Diabetes Mellitus and 26% only Insulin Resistance. These percentages were significantly higher in group with Parkinson's disease and dementia, also after adjustment for disease duration and motor disability.
CONCLUSIONS: Our study suggests that PD patients with dementia are two times more likely to have insulin resistance than patients with PD.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265943     DOI: 10.1016/j.jns.2011.12.008

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  38 in total

1.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

Review 2.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

3.  Aβ exacerbates α-synuclein-induced neurotoxicity through impaired insulin signaling in α-synuclein-overexpressed human SK-N-MC neuronal cells.

Authors:  Ching-Chi Chang; Hsin-Hua Li; Yen-Ting Chang; Ying-Jui Ho; Ling-Jia Hsieh; Pai-Yi Chiu; Yu-Shih Cheng; Chih-Li Lin; Te-Jen Lai
Journal:  CNS Neurosci Ther       Date:  2017-11-01       Impact factor: 5.243

Review 4.  Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.

Authors:  Sandeep Xxxx; Mir Hilal Ahmad; Linchi Rani; Amal Chandra Mondal
Journal:  Mol Neurobiol       Date:  2022-05-16       Impact factor: 5.590

Review 5.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 6.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

7.  Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

Authors:  Therese S Salameh; Elizabeth M Rhea; Konrad Talbot; William A Banks
Journal:  Biochem Pharmacol       Date:  2020-08-02       Impact factor: 5.858

8.  (-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus.

Authors:  Ning Jia; Kun Han; Jing-Jing Kong; Xiu-Mei Zhang; Sha Sha; Gui-Ru Ren; Yun-Peng Cao
Journal:  Mol Cell Biochem       Date:  2013-05-10       Impact factor: 3.396

Review 9.  Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.

Authors:  Medha Priyadarshini; Mohammad A Kamal; Nigel H Greig; Marcella Reale; Adel M Abuzenadah; Adeel G A Chaudhary; Ghazi A Damanhouri
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

Review 10.  Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs.

Authors:  Konrad Talbot
Journal:  Neurodegener Dis Manag       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.